• LAST PRICE
    3.8800
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    3.6800/ 10
  • Ask / Lots
    4.6800/ 4
  • Open / Previous Close
    0.0000 / 3.8800
  • Day Range
    ---
  • 52 Week Range
    Low 3.5100
    High 12.3950
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 3.92
TimeVolumeAEZS
09:32 ET1223.9
09:39 ET1203.82
09:42 ET2003.8323
10:58 ET2003.8103
11:14 ET1603.81
11:18 ET1003.9
11:57 ET12233.8
12:15 ET1003.9
12:17 ET2003.8499
12:19 ET17003.81
12:21 ET9003.8
12:42 ET1003.85
12:48 ET1003.89
01:24 ET13773.8
01:33 ET1003.88
02:23 ET1003.68
02:25 ET1003.68
02:30 ET3003.8296
03:15 ET1003.87
03:37 ET1003.84
03:42 ET1003.84
03:48 ET5003.88
04:00 ET1003.88
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAEZS
Aeterna Zentaris Inc
25.2M
-1.8x
---
United StatesJAGX
Jaguar Health Inc
18.9M
-0.2x
---
United StatesERYP
Erytech Pharma SA
20.3M
0.0x
---
United StatesPULM
Pulmatrix Inc
13.5M
-0.5x
---
United StatesHGEN
Humanigen Inc
16.9M
-0.1x
---
United StatesAMAM
Ambrx Biopharma Inc
18.5M
-0.2x
---
As of 2022-12-02

Company Information

Aeterna Zentaris Inc. is a specialty biopharmaceutical company, which is engaged in commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The Company focuses on the commercialization of macimorelin in Asia and the rest of the world.

Contact Information

Headquarters
Quebec, 1405 Boul Du Parc TechnologiqueQUEBEC, QC, Canada GIP 4P5
Phone
418-652-8525
Fax
418-948-9191

Executives

Non-Executive Independent Chairman of the Board
Carolyn Egbert
President, Chief Executive Officer, Director and Managing Director - AEZS Germany
Klaus Paulini
Chief Financial Officer, Senior Vice President
Giuliano La Fratta
Senior Vice President - Business Development and Alliance Management, Managing Director - Aeterna Zentaris GmbH
Eckhard Gunther
Senior Vice President - Clinical Development, Chief Medical Officer
Nicola Ammer

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$18.7M
Revenue (TTM)
$6.6M
Shares Outstanding
4.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.31
EPS
$-2.14
Book Value
$10.91
P/E Ratio
-1.8x
Price/Sales (TTM)
2.8
Price/Cash Flow (TTM)
---
Operating Margin
-221.38%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.